Clinical Trials Arena on MSN2d
Compass’s tovecimig meets primary endpoint in Phase II/III BTC trialCompass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...
RALEIGH, N.C., March 20, 2025 /PRNewswire/ -- Endpoint Clinical ("Endpoint"), a global leader in randomization and trial supply management ("RTSM") solutions and a portfolio company of Arsenal ...
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...
The evolution of the safety and effectiveness evaluation of endovascular grafts intended for abdominal aortic aneurysm repair ...
BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...
Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve survival compared with placebo in patients with locally advanced squamous cell ...
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage ... top-line data on the primary efficacy endpoint for COMPANION-002, the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback